Search Results
Your search for The A,The A matches 32372 pages
Showing 12401 - 12450Biomarker Analysis in the COMBI-AD Trial of Adjuvant Dabrafenib Plus Trametinib in BRAF V600–Mutant Stage III Melanoma
In an exploratory biomarker analysis from the COMBI-AD trial, reported in The Lancet Oncology, Dummer et al found that tumor mutational burden (TMB) and interferon-gamma gene-signature profiles might be associated with an augmented benefit of adjuvant dabrafenib plus trametinib in resected BRAF...
ASCO-SITC 2020: Ilixadencel/Sunitinib vs Sunitinib Alone in Synchronous Metastatic Kidney Cancer
In a study presented by Lindskog et al at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium (Abstract 11), researchers found ilixadencel, a cell-based allogeneic off-the-shelf product, in combination with sunitinib produced a higher objective response rate than sunitinib alone in patients with...
Five-Year Patient-Reported Outcomes for Various Prostate Cancer Treatments
A 5-year follow-up study of more than 2,000 U.S. men who received prostate cancer treatment—radiation, surgery, or active surveillance—in patients of all ages and ethnicities is creating a road map for the future regarding long-term bowel, bladder, and sexual function in order to clarify...
Genetic Mutations in Donor Stem Cells May Affect Hematopoietic Transplant Recipients
A new study on hematopoietic stem cell transplantation from Washington University School of Medicine in St. Louis suggests that extremely rare, harmful genetic mutations present in healthy donors’ stem cells—though not causing health problems in the donors—may be passed on to patients with cancer...
ASCO-SITC 2020: Low Incidence of Nivolumab-Induced Radiation Recall Pneumonitis Among Patients With NSCLC
A multicenter retrospective study investigating the incidence of pneumonitis and the incidence, risk factors, and clinical characteristics of radiation recall pneumonitis in patients with non–small cell lung cancer (NSCLC) who had received nivolumab found the incidence of radiation recall...
University of Maryland Greenebaum Comprehensive Cancer Center Joins Big Ten Cancer Research Consortium
The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) has joined the Big Ten Cancer Research Consortium. The Big Ten Cancer Research Consortium was created in 2013 to transform the conduct of cancer research through collaborative, hypothesis-driven, highly...
Expert Point of View: Michael Jain, MD, PhD
Michael Jain, MD, PhD, Assistant Member in the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center, Tampa, Florida, commented on Dr. Kilgore’s findings. Dr. Jain was coauthor of a study by the U.S. Lymphoma CAR T Consortium that presented real-world data...
Real-World Data for CAR T-Cell Therapy Show Benefit in Older Patients With Lymphoma, Lower Subsequent Health-Care Costs
Once considered highly experimental, chimeric antigen receptor (CAR) T-cell therapy is now an established third-line treatment option for B-cell lymphomas and leukemias. CAR T-cell therapy has saved the lives of people who would otherwise have run out of treatment options. But the question is...
Fox Chase Cancer Center Certified Under ASCO’s Quality Oncology Practice Initiative
Fox Chase Cancer Center has been recognized under ASCO’s Quality Oncology Practice Initiative (QOPI®) by the QOPI Certification Program LLC as successfully completing a 3-year certification for oncology practices that meet nationally recognized standards for quality and safety in cancer care. “Fox...
Stand Up To Cancer Announces Initiative to Increase Diversity in Clinical Trials
Stand Up To Cancer (SU2C) recently announced an initiative to increase minority representation in cancer clinical trials. All future SU2C-supported research grant proposals will now be required to include and address crucial issues related to recruitment and retention of patients from ethnic groups ...
ASH Presents 2019 Joanne Levy, MD, Memorial Award for Outstanding Achievement to Nicholas J. Short, MD
Nicholas J. Short, MD, of The University of Texas MD Anderson Cancer Center, Houston, received the 2019 Joanne Levy, MD, Memorial Award for Outstanding Achievement at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando. This annual award (which includes a...
Urology of Virginia Welcomes New Chief Medical Officer Joshua Langston, MD
Urology of Virginia has announced the transition of Joshua Langston, MD, to the role of Chief Medical Officer for the organization. He assumed this new position on January 1 and will continue the legacy of patient care, organizational guidance, innovation, and service of his predecessor, Dr. Edwin...
Susan Sturgeon, MPH, DrPH, Receives NIH Grant to Study Environmental Exposure on Breast Cancer Risk
University of Massachusetts Amherst (UMass Amherst) cancer epidemiologist, and Professor of Biostatistics and Epidemiology in the School of Public Health and Health Sciences, Susan Sturgeon, MPH, DrPH, has received a $462,000 grant from the National Institutes of Health (NIH) to expand her research ...
Fox Chase Cancer Center Welcomes Claudia J. Kasales, MD, MHA, FACR
Fox Chase Cancer Center has announced the hiring of Claudia J. Kasales, MD, MHA, FACR, who will join the Department of Diagnostic Imaging as Professor on the academic clinician track. Dr. Kasales began work at Fox Chase on February 1, 2020. Dr. Kasales comes to Fox Chase from Penn State Health...
Is There a Future Role for Secondary Cytoreductive Surgery in the Treatment of Recurrent Ovarian Cancer?
In a recent issue of The New England Journal of Medicine, Coleman et al released the results from the GOG-0213 trial, a multicenter, randomized prospective trial that compared secondary cytoreduction followed by chemotherapy with chemotherapy alone in women with platinum-sensitive recurrent ovarian ...
Expert Point of View: Sara M. Tolaney, MD, MPH
Sara M. Tolaney, MD, MPH, Assistant Professor of Medicine at Harvard Medical School and Associate Director of the Susan F. Smith Center for Women’s Cancers at Dana-Farber/Brigham and Women’s Cancer Center, Boston, commented on KEYNOTE-890. “Previous work has suggested minimal activity of...
Triple-Negative Breast Cancer Responds to Novel Therapy
The phase II KEYNOTE-890 trial is a small but interesting study in patients with inoperable advanced triple-negative breast cancer. After one injection of intratumoral tavokinogene telseplasmid, a plasmid encoding the proinflammatory cytokine interleukin-12 (IL-12), followed by electroporation and...
Neoadjuvant and Adjuvant Pembrolizumab Improves Pathologic Complete Response Rate in Triple-Negative Breast Cancer
The addition of pembrolizumab to neoadjuvant and adjuvant chemotherapy achieves higher rates of pathologic complete response compared with placebo in patients with triple-negative breast cancer, according to results of the phase III KEYNOTE-522 trial presented at the 2019 San Antonio Breast Cancer...
BEACON CRC: Patient-Reported Quality of Life Results
This week, we’ll be featuring three researchers discussing findings presented at the 2020 Gastrointestinal Cancers Symposium: Dr. Scott Kopetz, of The University of Texas MD Anderson Cancer Center, discusses quality-of-life results from the BEACON CRC trial in BRAF V600E–mutated colorectal cancer;...
Study Finds Women With Variants in Breast Cancer–Associated Genes May Not Always Be Receiving Guideline-Concordant Care
Women with early-stage breast cancer who test positive for an inherited genetic variant are not always receiving cancer treatment that follows current treatment guidelines, according to findings from a new study published by Allison W. Kurian, MD, MSc, and colleagues in JAMA Oncology. An inherited ...
Do Socioeconomic Factors Play a Role in Outcomes for HPV-Positive Head and Neck Cancer?
Survival outcomes for patients with human papillomavirus (HPV)-positive squamous cell carcinoma of the head and neck have made significant gains in recent years, but new research published by Pike et al in JNCCN—Journal of the National Comprehensive Cancer Network has found some groups have not...
Expert Point of View: Jeremy S. Abramson, MD
Jeremy S. Abramson, MD, Director of the Jon and JoAnn Hagler Center for Lymphoma at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, Boston, commented on the study by Topp et al for The ASCO Post. “Earlier use of steroids with axicabtagene ciloleucel...
ASCO-SITC 2020: Preliminary Results Show Antitumor Activity With Pepinemab/Avelumab in Patients With Advanced NSCLC
Interim results from the CLASSICAL-Lung phase Ib/II clinical trial of pepinemab, an IgG4 humanized monoclonal antibody targeting semaphorin 4D, in combination with the anti–programmed cell death ligand 1 antibody avelumab for patients with advanced NSCLC showed that the treatment is well tolerated...
Damon Runyon Cancer Research Foundation Awards Early-Career Scientists
The Damon Runyon Cancer Research Foundation recently announced that 12 scientists with novel approaches to fighting cancer have been named the 2020 recipients of the Damon Runyon-Rachleff Innovation Award. Six initial grants of $400,000 over 2 years were awarded to seven early-career scientists...
Douglas Hanahan, PhD, Appointed Distinguished Scholar of the Ludwig Institute for Cancer Research
Ludwig Cancer Research has announced the appointment of Douglas Hanahan, PhD, as a Distinguished Scholar at the Lausanne Branch of the Ludwig Institute for Cancer Research. A molecular biologist and cancer researcher, Dr. Hanahan has made several seminal discoveries in cancer biology and...
Genomics-Guided Molecular Targeted Therapy Gave Me Back My Life
In October 2014, I noticed a small pea-sized lump on the left side of my cheek. It didn’t hurt, and I didn’t have any physical symptoms that could connect the lump with a rare and serious disease, but I was curious enough about what the lump could be to get it checked out by my primary care...
ASCO-SITC 2020: Vitamin D May Reduce Risk for Immune Checkpoint Inhibitor–Associated Colitis
In a study to be presented by Tyan et al at the upcoming 2020 ASCO-SITC Clinical Immuno-Oncology Symposium (Abstract 89), researchers found that vitamin D intake may be associated with reduced risk of colitis among patients being treated with immune checkpoint inhibitors. Retrospective Analysis In ...
Laura van ’t Veer, PhD, Honored With Precision Medicine World Conference Luminary Award
Laura van’t Veer, PhD, Co-Founder of Agendia Inc. and developer of MammaPrint, the 70-gene risk of recurrence assay for patients with breast cancer, was recognized at the Precision Medicine World Conference (PMWC) with its Luminary Award. This award recognizes those individuals who have made...
Prevent Cancer Foundation Benefits Global Cancer Research
The gaming community showed their support to the oncology community by donating proceeds throughout a 10th Anniversary celebration of a week-long, 24-hour, speedrunning marathon. The charity event, Awesome Games Done Quick (AGDQ), concluded on January 12, 2020, raising a total of $3.13 million, the ...
Dolores Hambardzumyan, PhD, MBA, Joins Neurosurgery Faculty at Mount Sinai
Dolores Hambardzumyan, PhD, MBA, has been appointed Senior Faculty in the Department of Neurosurgery and a member of The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. Her research focuses on developing novel therapeutic pathways for the treatment of glioblastoma. She is...
Seattle Cancer Care Alliance Appoints Aaron Crane as Executive Vice President
Seattle Cancer Care Alliance (SCCA) has announced Aaron Crane as the new Executive Vice President. Mr. Crane will lead the organization’s strategic development, including its long-range financial plan and the upcoming clinic expansion at the South Lake Union campus. Since joining the organization...
Karen L. Reckamp, MD, MS, to Head Medical Oncology at Cedars-Sinai Cancer
Lung cancer expert Karen L. Reckamp, MD, MS, has been selected to be Director of the Division of Medical Oncology at Cedars-Sinai Cancer. Dr. Reckamp also will serve as Medical Oncology Director of the Women’s Guild Lung Institute in Cedars-Sinai’s Department of Medicine and Associate Director for ...
Denial’s Many Faces
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Addressing Symptom Control and Palliative Care Needs
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Gabriel Lopez, MD, emphasizes the importance of effective communication and...
Doctoring in the Digital Age: Modern Stressors, Ancient Strategies to Cope
In my 45 years of practicing hematology/oncology at a major urban academic medical center, I have observed a sea change in daily practice that contributes to physician burnout. Although the emotional stresses of caring for seriously ill people play a part in physician burnout, I find the daily...
Early Steroid Use May Reduce Toxicity With CAR T-Cell Therapy
In patients with large B-cell lymphoma undergoing chimeric antigen receptor (CAR) T-cell therapy with axicabtagene ciloleucel, earlier-than-usual intervention with corticosteroids and tocilizumab may reduce the incidence of severe cytokine-release syndrome, according to the findings of a...
A Retired Oncologist Remains Involved in the Science and Policy of Oncology
The history of medicine once was featured in medical school curricula. That is becoming less common due to time restriction and the increased prevalence of more technical topics. However, the importance of the history of medicine cannot be overstated: It shapes every aspect of our cultural,...
Comparing Prescribing Habits in Academic and Nonacademic Oncology Settings
The art of oncology practice is tailored to the individual patient with cancer, and with the advent of highly personalized targeted therapies, patient outcomes have improved markedly over the past several decades. Although much of oncology practice is guideline- or protocol-driven, chemotherapy...
Incidence Increases in New Colorectal Cancer Diagnoses Among Patients Between 49 and 50 Years Old
A year-by-year age analysis of colorectal cancer rates among adults in the United States has found a 46% increase in new diagnoses from ages 49 to 50, indicating that many latent cases of the disease are likely going undiagnosed until routine screenings begin at 50, according to a new study by...
Is Distance to Treatment a Burden for Rural Patients With Breast Cancer?
A study published by Longacre et al in The Journal of Rural Health found that patients with breast cancer in the rural United States typically travel three times farther than those who live in urban areas for radiation therapy. Researchers examined data from the Surveillance, Epidemiology, and End ...
Circulating Tumor Cell Assessment to Predict Melanoma Relapse
A study published by Anthony Lucci, MD, and colleagues in Clinical Cancer Research showed that the presence of circulating tumor cells was independently associated with relapse of melanoma, suggesting circulating tumor cell assessment may be a useful tool for identifying patients at risk for...
Effect of Volume-Based CT Screening on Lung Cancer Mortality in High-Risk Patients
As reported in The New England Journal of Medicine by Harry J. de Koning, MD, PhD, and colleagues, the Dutch/Belgian NELSON trial has shown a significant reduction in 10-year lung cancer mortality with volume-based low-dose computed tomography (CT) screening vs no screening in high-risk men. Male...
Clinical Cancer Advances 2020: ASCO Names Advance of the Year, Issues Research Priorities for the Cancer Community
In the release of its annual report on progress against cancer, Clinical Cancer Advances 2020, ASCO recognized progress in the refinement of the surgical treatment of cancer as the Advance of the Year. In particular, the emergence of novel systemic therapies—combined in new and better ways—has...
ASCO Guideline Addresses Surveillance of Lung Cancer After Curative-Intent Therapy
ASCO has released a new guideline providing recommendations to practicing clinicians on radiographic imaging and biomarker surveillance strategies after definitive, curative-intent therapy in patients with stage I to III non–small cell lung cancer or small cell lung cancer. These guideline...
Diffusion-Weighted MRI May Help Predict Treatment Response in Patients With Advanced Ovarian Cancer
A simple test using a magnetic resonance imaging (MRI) scan may be used to predict how well people with advanced epithelial ovarian cancer will respond to treatment, according to the results of a new study published by Winfield et al in Radiology. In a large clinical trial, scientists have shown a...
WHO, IARC Release Reports in Response to Government’s Role in Cancer Control
The World Health Organization (WHO) and the International Agency for Research on Cancer (IARC) released two coordinated reports in light of World Cancer Day in response to government calls for more research into the scope and potential policies and programs to improve cancer control. WHO Report...
World Cancer Day 2020: 20th Anniversary of the Global Initiative
Today’s World Cancer Day, led by the Union for International Cancer Control (UICC), aims to mobilize urgent action from individuals, governments, and the global cancer community to close gaps in cancer risk awareness between higher and lower socioeconomic groups and the subsequent impact on their...
CAR T-Cell Gene Therapy in Non-Hodgkin Lymphomas: Present and Future
To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel immunotherapies for patients with different types of non-Hodgkin...
Selected ASH Abstracts on Myelodysplastic Syndromes
To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapies for myelodysplastic syndromes (MDS), including the...
Actively Recruiting Clinical Trials for Cervical Cancer
This Clinical Trials Resource Guide lists actively recruiting clinical trials that focus on cervical cancer. They are examining the efficacy of adding nelfinavir to treatment regimens, using atezolizumab as an immunotherapy primer, combining metformin and doxycycline, adjuvant chemotherapy in...
